Phreesia, Inc. (PHR) Securities Class Action Lawsuit Update

• Case Name: Theodoulou v. Phreesia, Inc., et al.
• Case No.: 1:26-cv-00556
• Jurisdiction: United States District Court for the District of Delaware
• Filed on: May 13, 2026
• Class Period: May 8, 2025 through March 30, 2026

Introduction

A federal securities class action has been filed in the United States District Court for the District of Delaware against Phreesia, Inc. and two of its top executives, Chief Executive Officer Chaim Indig and Chief Financial Officer Balaji Gandhi. The complaint, brought on behalf of all investors who purchased or otherwise acquired Phreesia common stock between May 8, 2025, and March 30, 2026, inclusive, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

At the heart of the case is a familiar arc: executives painting an optimistic portrait of the company's growth trajectory, reassuring investors quarter after quarter that the business was firing on all cylinders, while allegedly concealing deepening cracks in its fastest-growing revenue engine. During the class period, Defendants repeatedly touted Phreesia's Network Solutions segment as a durable growth driver, highlighted expanding pharmaceutical marketing commitments, pointed to the AccessOne acquisition as a catalyst, and maintained robust revenue guidance for fiscal year 2027 at $545 million to $559 million. The complaint alleges investors purchased Phreesia shares at artificially inflated prices.

Then, after the market closed on March 30, 2026, Phreesia announced reduced fiscal 2027 guidance. The company slashed its fiscal 2027 revenue outlook to $510 million to $520 million, citing "worsening visibility" and weaker pharmaceutical marketing commitments within its Network Solutions segment. The reaction was swift and severe: Phreesia's stock price collapsed from $11.41 to $8.38 per share in a single trading session, a decline of approximately 27%.

> “Most PHR shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Phreesia is a healthcare technology company trading on the NYSE under the ticker “PHR.” The complaint describes Phreesia as an integrated SaaS-based software and payment platform serving the healthcare industry in the United States and Canada, with tools for digital check-in, scheduling and referral workflows, patient payments, financing, data capture, and analytics.

Phreesia completed its IPO in July 2019 at $18.00 per share, raising approximately $140.6 million in gross proceeds for the company before underwriting discounts, commissions, and expenses. Its business includes three revenue streams: subscription and related services, payment solutions, and Network Solutions. In fiscal 2026, Phreesia reported $480.6 million in total revenue and $2.3 million in net income, while its platform facilitated approximately 180 million patient visits, or about one in six U.S. ambulatory visits.

Network Solutions is central to the complaint’s allegations. The complaint alleges that Defendants made positive statements about Phreesia’s growth outlook, including Network Solutions expansion and expected contributions from the AccessOne acquisition, while allegedly concealing slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments. The complaint further alleges that, on March 30, 2026, Phreesia lowered its fiscal 2027 revenue outlook from $545 million–$559 million to $510 million–$520 million, citing shorter visibility into spending commitments by certain pharmaceutical manufacturers and lower second-half fiscal 2027 commitments from Network Solutions clients.

Promises Made vs. Reality

Throughout the class period, Phreesia's leadership built a narrative of momentum and expansion, anchored by the Network Solutions segment and its pharmaceutical marketing partnerships. On May 28, 2025, the company published first quarter fiscal 2026 results, and CEO Chaim Indig declared the fiscal year was "off to a strong start," expressing gratitude for a team whose performance was "a reflection of our team truly living our values." CFO Balaji Gandhi reinforced the message, telling investors the results demonstrated "our team's focus on growing our network, expanding our offerings and driving operating leverage." When J.P. Morgan analyst Anne Elizabeth Samuel asked about pharmaceutical client decision-making, Gandhi pointed to Phreesia being a "product-led company" and emphasized its strong product development pipeline. Later, when Stephens analyst Jeffrey Garro asked about Network Solutions seasonality, Gandhi assured investors that "the visibility we have into the year is the same as it was last year at this time."

Indig himself went further, characterizing Phreesia as "more often than not the platform that is the receiver of dollars throughout the year just because of our very strong ROI and our ability to deliver results." When Stephens analyst Jeffrey Garro asked about seasonality in Network Solutions, Gandhi told investors there was "nothing really to call out" beyond normal quarter-to-quarter fluctuations. By September 4, 2025, the drumbeat grew louder. The company announced the acquisition of AccessOne and its first-ever net income positive quarter. Gandhi stated that Phreesia increased its Network Solutions TAM by $6 billion and that the combined payments and Network Solutions addressable market was expected to increase to approximately $24 billion, and assured investors the team was "in a similar place we were last year at this time." Indig told investors that VoiceAI was "growing rapidly" and called the feedback from the provider network "like nothing I've seen ever before," while Gandhi assured analysts the company was "in a similar place we were last year at this time" regarding Network Solutions visibility.

The crescendo came on December 8, 2025, when Defendants formally introduced fiscal 2027 revenue guidance of $545 million to $559 million, representing a 14-16% increase over fiscal 2026. Indig spotlighted "emerging products" in provider financing and HCP marketing as new growth levers, proclaiming that "no one else in the market can do as comprehensively as Phreesia" what the company was building. Gandhi reiterated that "network solutions would be growing the fastest" among Phreesia's segments and told Truist analyst Jailendra Singh the company could "comfortably say that we're in a similar situation we were last year at this time." According to the complaint, these statements created the impression that Phreesia was well positioned to capitalize on its growth initiatives and that Network Solutions remained on track.

But on March 30, 2026, the story unraveled. Phreesia disclosed that Network Solutions clients were "committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December." The company cited "shorter visibility into spending commitments by certain pharmaceutical manufacturers" and acknowledged "more variability" in its internal forecasting. Gandhi described the booking environment as “very fluid” and cited vaccines, public health, and specific brand and therapeutic areas as examples of where Phreesia was seeing pullbacks. Revenue guidance for fiscal 2027 was cut to $510 million to $520 million, a reduction of $35 million at the low end and $39 million at the high end, or $37 million at the midpoint. As alleged in the complaint, Defendants had created the false impression of reliable growth while possessing information suggesting that pharmaceutical marketing commitments were weakening and the 2027 revenue target was at risk.

Timeline of Alleged Misconduct and Disclosures

Class Period: May 8, 2025 - March 30, 2026, inclusive.

May 28, 2025: Phreesia reports Q1 fiscal 2026 results. Maintains fiscal 2026 revenue guidance of $472 million to $482 million. CEO Indig states fiscal year is "off to a strong start." CFO Gandhi assures visibility into the year "is the same as it was last year at this time." EBITDA guidance raised.

September 4, 2025: Phreesia reports Q2 fiscal 2026 results. Reaffirms fiscal 2026 revenue guidance. Announces acquisition of AccessOne. Achieves first-ever net income positive quarter. Gandhi expands Network Solutions TAM by $6 billion. Indig describes VoiceAI feedback as "like nothing I've seen ever before." Gandhi tells analysts the company is "in a similar place we were last year at this time."

November 12, 2025: AccessOne acquisition closes.

December 8, 2025: Phreesia reports Q3 fiscal 2026 results. Introduces fiscal 2027 revenue guidance of $545 million to $559 million, representing 14-16% growth. Narrows fiscal 2026 revenue guidance to $479 million to $481 million. Raises EBITDA guidance to $99 million to $101 million. Indig highlights "emerging products" and HCP marketing as new growth levers.

Gandhi states Network Solutions "would be growing the fastest" and characterizes the selling season as reflecting progress.

March 30, 2026 (CORRECTIVE DISCLOSURE): Phreesia announces Q4 and full year fiscal 2026 results. Slashes fiscal 2027 revenue guidance to $510 million to $520 million. Cites "worsening visibility" and weaker pharmaceutical marketing commitments within Network Solutions. Indig acknowledges "shorter visibility" and "challenges" in the healthcare industry.

Gandhi describes the booking environment as "very fluid" and concedes clients are committing fewer dollars. Stock declines approximately 27% the following trading day.

Investor Harm and Market Reaction

The complaint ties investor losses directly to the March 2026 disclosure.

The complaint alleges that the March 30, 2026 disclosure caused immediate financial harm to Phreesia shareholders. On March 31, 2026, Phreesia’s stock declined from a prior closing price of $11.41 to $8.38, a drop of about 27%.

The complaint alleges that analyst reactions showed investors placed significant weight on Phreesia’s Network Solutions segment and its guidance. According to the complaint, Phreesia’s repeated guidance statements and Network Solutions commentary built investor confidence leading up to the March 2026 disclosure. That guidance had been set at a level management described as reflecting "progress" in the Network Solutions selling season. Analysts later focused on the reduced visibility and lower Network Solutions spend commitments.

The revised range represented a $35 million reduction at the low end and a $39 million reduction at the high end, or a $37 million midpoint reduction, and management had said Network Solutions would be the company’s fastest-growing segment. The complaint alleges that the stock’s decline to $8.38, a single-day drop of approximately 27% from the prior close of $11.41, reflected the removal of artificial inflation from Phreesia’s share price.

Litigation and Procedural Posture

The lawsuit was filed on May 13, 2026, in the United States District Court for the District of Delaware on behalf of investors who purchased Phreesia common stock during the proposed class period. The defendants include Phreesia, Inc., CEO and Director Chaim Indig, and CFO Balaji Gandhi. The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all Defendants, as well as claims under Section 20(a) of the Exchange Act against the Individual Defendants as controlling persons of the Company.

Scienter allegations center on the Individual Defendants’ CEO and CFO roles, which allegedly gave them actual knowledge of, or access to, non-public information concerning Phreesia's slowing demand in its Network Solutions segment. The complaint alleges that Defendants possessed the power and authority to control the contents of Phreesia's public disclosures and knew that adverse facts had not been disclosed to investors. No insider trading allegations are specifically pleaded. No confidential witness testimony is cited at this stage.

Procedurally, the case is in its earliest stages, having been filed in May 2026 in the District of Delaware. The complaint seeks class certification on behalf of all purchasers of Phreesia common stock during the class period who were damaged upon the revelation of the corrective disclosure. Lead plaintiff submissions are due July 13, 2026. As of the filing date, approximately 60.7 million shares of Phreesia common stock were outstanding.

SEC Filings & Risk Factors

The complaint focuses on a series of press releases and earnings call statements made during the class period, rather than specific periodic SEC filings such as 10-Ks or 10-Qs, as the primary vehicles for the alleged misrepresentations. However, the pattern of disclosure across the three quarterly reporting cycles paints a clear picture of the gap between what Defendants told investors and what was ultimately revealed.

In its first quarter fiscal 2026 press release on May 28, 2025, Phreesia maintained revenue guidance of $472 million to $482 million and raised its EBITDA outlook. The complaint does not identify any warning in that release about deteriorating pharmaceutical marketing visibility. During the accompanying earnings call, Gandhi affirmatively stated that the company's visibility into the year was "the same as it was last year at this time," and Indig characterized Phreesia as a reliable "receiver of dollars" from pharmaceutical clients.

It introduced the AccessOne acquisition and stated that Phreesia increased its Network Solutions TAM by $6 billion, while the combined payments and Network Solutions addressable market was expected to increase to approximately $24 billion. The complaint does not identify any contemporaneous disclosure warning that pharmaceutical marketing visibility had deteriorated in the way allegedly revealed on March 30, 2026. Gandhi reiterated to analysts that the company was "in a similar place we were last year at this time."

The third quarter fiscal 2026 press release on December 8, 2025, represented the high-water mark: fiscal 2027 guidance was introduced at $545 million to $559 million, fiscal 2026 revenue guidance was narrowed upward, and EBITDA guidance was raised substantially. The quarterly stakeholder letter and earnings call highlighted "emerging products" and new market opportunities as growth catalysts. Gandhi told analysts the company could "comfortably say" its position in the Network Solutions selling season was consistent with prior years and projected that Network Solutions would be the fastest-growing segment.

According to the complaint, the March 30, 2026 disclosure revealed what earlier statements had allegedly omitted: pharmaceutical marketing clients were committing lower spend levels for the second half of fiscal 2027 than Defendants had anticipated, visibility into Network Solutions commitments had shortened materially, and the revenue forecasting process contained "more variability" than previously disclosed.

The complaint alleges these conditions were developing during the class period and made Defendants’ earlier assurances misleading when made.

How to Join the Phreesia (PHR) Class Action

• Confirm you purchased PHR shares during the relevant class period between May 8, 2025 and March 30, 2026
• Review eligibility details and transaction records
• Contact class counsel or a securities litigation attorney to evaluate potential participation
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.